Cargando…

Serum markers of multiple sclerosis - a new approach

Detalles Bibliográficos
Autor principal:	Torkildsen, Øivind
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847952/ https://www.ncbi.nlm.nih.gov/pubmed/33516064 http://dx.doi.org/10.1016/j.ebiom.2021.103229

Ejemplares similares

Extensive Multiple Sclerosis Reactivation after Switching from Fingolimod to Rituximab
por: Holmøy, Trygve, et al.
Publicado: (2018)

An Update on Vitamin D and Disease Activity in Multiple Sclerosis
por: Smolders, Joost, et al.
Publicado: (2019)

Neurofilament Light Chain as a Biomarker in Multiple Sclerosis
por: Varhaug, Kristin N., et al.
Publicado: (2019)

Safety of breast feeding during rituximab treatment in multiple sclerosis
por: Rød, Brit Ellen, et al.
Publicado: (2023)

Epstein-Barr Virus in Systemic Lupus Erythematosus, Rheumatoid Arthritis and Multiple Sclerosis—Association and Causation
por: Lossius, Andreas, et al.
Publicado: (2012)

Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis – A cohort study
por: Torgauten, Hilde Marie, et al.
Publicado: (2021)

Natural Variation of Vitamin D and Neurofilament Light Chain in Relapsing-Remitting Multiple Sclerosis
por: Røsjø, Egil, et al.
Publicado: (2020)

Microstructural changes precede depression in patients with relapsing-remitting Multiple Sclerosis
por: Riemer, Frank, et al.
Publicado: (2023)

Abuse and revictimization in adulthood in multiple sclerosis: a cross-sectional study during pregnancy
por: Eid, Karine, et al.
Publicado: (2022)

Association of adverse childhood experiences with the development of multiple sclerosis
por: Eid, Karine, et al.
Publicado: (2022)

Fungal microbiome and multiple sclerosis: The not-so-new kid on the block
por: Mangalam, Ashutosh K.
Publicado: (2021)

Patient Power Revolution in Multiple Sclerosis: Navigating the New Frontier
por: Yeandle, David, et al.
Publicado: (2018)

Month of birth and risk of multiple sclerosis: confounding and adjustments
por: Torkildsen, Øivind, et al.
Publicado: (2014)

Inflammation Markers in Multiple Sclerosis: CXCL16 Reflects and May Also Predict Disease Activity
por: Holmøy, Trygve, et al.
Publicado: (2013)

Price Increases and New Drugs Drive Increased Expenditures for Multiple Sclerosis
por: Schafer, Jeremy A., et al.
Publicado: (2010)

Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

Reply to comment: Month of birth and risk of multiple sclerosis: confounding and adjustments
por: Torkildsen, Øivind, et al.
Publicado: (2014)

Tolerogenic vaccines for Multiple Sclerosis
por: Mannie, Mark D., et al.
Publicado: (2013)

Perinatal Depression and Anxiety in Women With Multiple Sclerosis: A Population-Based Cohort Study
por: Eid, Karine, et al.
Publicado: (2021)

Luteolin as a therapeutic option for multiple sclerosis
por: Theoharides, Theoharis C
Publicado: (2009)

Disease-modifying treatments for multiple sclerosis – a review of approved medications
por: Torkildsen, Ø, et al.
Publicado: (2016)

Chewing the fat on an emerging target in multiple sclerosis
por: Lim, Chai K.
Publicado: (2021)

The Extracellular Matrix and Remyelination Strategies in Multiple Sclerosis
por: You, Yuyi, et al.
Publicado: (2018)

An insight about genomic susceptibility & multiple sclerosis
por: Verma, Rajesh, et al.
Publicado: (2017)

European and American Guidelines for Multiple Sclerosis Treatment
por: Ghezzi, Angelo
Publicado: (2018)

Seeking neuroprotection in multiple sclerosis: an ongoing challenge
por: Antel, Jack P., et al.
Publicado: (2023)

No association of tobacco use and disease activity in multiple sclerosis
por: Kvistad, Silje, et al.
Publicado: (2016)

Pivotal Trials in Multiple Sclerosis: Similarities Prove Not to Be Useful
por: Avolio, Carlo, et al.
Publicado: (2021)

Multiple sclerosis: major histocompatibility complexity and antigen presentation
por: Ramagopalan, Sreeram V, et al.
Publicado: (2009)

B cells and multiple sclerosis spinal cord pathology
por: Schmierer, Klaus, et al.
Publicado: (2020)

Monkeypox in Multiple Sclerosis patients: Should we be alert?
por: Boldrini, Vinícius Oliveira, et al.
Publicado: (2022)

Alpha-tocopherol and MRI Outcomes in Multiple Sclerosis – Association and Prediction
por: Løken-Amsrud, Kristin I., et al.
Publicado: (2013)

The effect of gadolinium-based contrast-agents on automated brain atrophy measurements by FreeSurfer in patients with multiple sclerosis
por: Lie, Ingrid Anne, et al.
Publicado: (2022)

A multiple sclerosis patient-oriented multiomics analysis tells us where to go next: Commentary for: “Alterations of host-gut microbiome interactions in multiple sclerosis”
por: Yamamura, Takashi, et al.
Publicado: (2022)

Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades
por: Grytten, N, et al.
Publicado: (2015)

Relationship Between White Matter Lesions and Gray Matter Atrophy in Multiple Sclerosis: A Systematic Review
por: Lie, Ingrid Anne, et al.
Publicado: (2022)

COVID-19 pandemic: The experience of a multiple sclerosis centre in Chile
por: Ciampi, Ethel, et al.
Publicado: (2020)

Similarities and differences between multiple sclerosis and type 1 diabetes
por: Pozzilli, Valeria, et al.
Publicado: (2021)

Honing in on magnetic resonance imaging predictors of multiple sclerosis pathology
por: Schmierer, Klaus
Publicado: (2023)

Paradigms in multiple sclerosis: time for a change, time for a unifying concept
por: Krone, Bernd, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_3tn89tpb0789jnef35l0u8elaa